Population-based estimate for the correlation of the Oncotype Dx Breast Recurrence Score® result and Ki-67 IHC MIB-1 pharmDx in HR+, HER2−, node-positive early breast cancer

Population-based estimate for the correlation of the Oncotype Dx Breast Recurrence Score® result and Ki-67 IHC MIB-1 pharmDx in HR+, HER2−, node-positive early breast cancer

Abstract Background The United States Food and Drug Administration recently approved a Ki-67 immunohistochemistry (IHC) assay to identify patients with early breast cancer at high disease recurrence risk. The Oncotype Dx Breast Recurrence Score® assay has been validated in hormone receptor-positive...

Full description

Bibliographic Details
Main Authors: Michael Crager, Sameera R. Wijayawardana, Aaron M. Gruver, Andrea Blacklock, Christy Russell, Frederick L. Baehner, Francisco Sapunar
Format: Article
Language:English
Published: BMC 2022-11-01
Series:Breast Cancer Research
Subjects:
Early breast cancer
Immunohistochemistry
Ki-67
MIB-1
Oncotype Dx
Recurrence score
Online Access:https://doi.org/10.1186/s13058-022-01571-7

Internet

https://doi.org/10.1186/s13058-022-01571-7

Similar Items